Spero Therapeutics (SPRO) News Today $2.07 +0.07 (+3.50%) Closing price 04:00 PM EasternExtended Trading$2.08 +0.01 (+0.48%) As of 07:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SPRO Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Anson Funds Management LP Has $5.50 Million Position in Spero Therapeutics, Inc. $SPROAugust 26 at 8:11 AM | marketbeat.comSpero Therapeutics (NASDAQ:SPRO) Stock Passes Above 200-Day Moving Average - Here's What HappenedAugust 25, 2025 | marketbeat.comSpero Therapeutics (NASDAQ:SPRO) Releases Earnings Results, Beats Expectations By $0.32 EPSAugust 14, 2025 | marketbeat.comSpero Therapeutics, Inc. (NASDAQ:SPRO) Q2 2025 Earnings Call TranscriptAugust 13, 2025 | insidermonkey.comSpero Therapeutics, Inc.: Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business UpdateAugust 13, 2025 | finanznachrichten.deSpero Therapeutics Reports Q2 2025 Results and Trial SuccessAugust 13, 2025 | msn.comSpero Therapeutics Reports Q2 2025 Financial ResultsAugust 12, 2025 | msn.comSpero Therapeutics, Inc. (SPRO) Q2 2025 Earnings Call TranscriptAugust 12, 2025 | seekingalpha.comSpero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business UpdateAugust 12, 2025 | globenewswire.comSpero Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 12, 2025August 5, 2025 | globenewswire.comSpero Therapeutics (SPRO) Expected to Announce Quarterly Earnings on MondayJuly 28, 2025 | marketbeat.comSpero Therapeutics (NASDAQ:SPRO) Stock Passes Above Fifty Day Moving Average - What's Next?July 1, 2025 | marketbeat.comWhile institutions own 20% of Spero Therapeutics, Inc. (NASDAQ:SPRO), retail investors are its largest shareholders with 54% ownershipJune 28, 2025 | finance.yahoo.comSpero Therapeutics, Inc. (SPRO) Cash Flow - Yahoo FinanceJune 26, 2025 | finance.yahoo.comSpero Therapeutics (NASDAQ:SPRO) Upgraded to "Hold" at Wall Street ZenJune 21, 2025 | marketbeat.comSpero Therapeutics (NASDAQ:SPRO) Shares Pass Above 200 Day Moving Average - What's Next?June 19, 2025 | marketbeat.comSpero Therapeutics, Inc. (NASDAQ:SPRO) Short Interest Up 446.6% in MayJune 11, 2025 | marketbeat.comSpero Therapeutics -- Additional Upside Potential Following Positive Phase 3 ResultsJune 11, 2025 | seekingalpha.comSpero Therapeutics, Inc. (NASDAQ:SPRO) Stake Boosted by Mackenzie Financial CorpJune 6, 2025 | marketbeat.comWhy Spero Therapeutics, Inc. (SPRO) Surged Last WeekMay 31, 2025 | msn.comBest Penny Stocks To Watch Today - May 28thMay 30, 2025 | marketbeat.comSpero Therapeutics Jumps as Oral Carbapenem Hits Phase 3 MilestoneMay 29, 2025 | msn.comSpero Therapeutics Sees Unusually Large Options Volume (NASDAQ:SPRO)May 29, 2025 | marketbeat.comSpero Therapeutics Shares Soar as Trial with GSK Ends Early on EfficacyMay 28, 2025 | marketwatch.comSpero Therapeutics Stock Skyrockets on Strong Phase 3 Trial ResultsMay 28, 2025 | msn.comSpero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring CommitteeMay 28, 2025 | globenewswire.comSpero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business UpdateMay 13, 2025 | globenewswire.comSpero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on Tuesday, May 13, 2025May 5, 2025 | globenewswire.comSpero Therapeutics, Inc.: Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive OfficerApril 29, 2025 | finanznachrichten.deSpero Therapeutics Appoints Esther Rajavelu as President and Chief Executive OfficerApril 28, 2025 | globenewswire.comSpero Therapeutics Analyst RatingsApril 7, 2025 | benzinga.comTD Cowen Sticks to Their Hold Rating for Spero Therapeutics (SPRO)April 2, 2025 | markets.businessinsider.comWe're Keeping An Eye On Spero Therapeutics' (NASDAQ:SPRO) Cash Burn RateMarch 29, 2025 | finance.yahoo.comSpero Therapeutics reports Q4 EPS (38c), consensus (31c)March 28, 2025 | markets.businessinsider.comSpero Therapeutics, Inc.: Spero Therapeutics Announces Fourth Quarter and Full Year 2024 Operating Results and Provides a Business UpdateMarch 28, 2025 | finanznachrichten.deSpero Therapeutics, Inc. (SPRO) Q4 2024 Earnings Call TranscriptMarch 27, 2025 | seekingalpha.comSpero Therapeutics Announces Fourth Quarter and Full Year 2024 Operating Results and Provides a Business UpdateMarch 27, 2025 | globenewswire.com1SPRO : A Glimpse of Spero Therapeutics's Earnings PotentialMarch 26, 2025 | benzinga.comSpero Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 27, 2025March 18, 2025 | globenewswire.comUPDATE – Spero Therapeutics to Present at TD Cowen 45th Annual Health Care ConferenceFebruary 25, 2025 | globenewswire.comSpero Therapeutics to Present at TD Cowen 45th Annual Health Care ConferenceFebruary 25, 2025 | globenewswire.comSpero Therapeutics CEO sells shares worth $121,159February 6, 2025 | msn.comSpero Therapeutics, Inc. (NASDAQ:SPRO) CFO Esther Rajavelu Sells 20,689 SharesFebruary 6, 2025 | insidertrades.comSpero therapeutics CFO sells $16,137 in stockFebruary 5, 2025 | msn.comSpero Therapeutics COO Timothy Keutzer sells shares for $44,097February 5, 2025 | msn.comOptimistic Buy Rating for Spero Therapeutics Amid Strategic Initiatives and PartnershipsJanuary 30, 2025 | markets.businessinsider.comSpero Therapeutics Inc SPROJanuary 16, 2025 | morningstar.comMSpero Therapeutics, Inc.: Spero Therapeutics Provides Business Update and Announces Interim Leadership ChangesJanuary 10, 2025 | finanznachrichten.deSpero Therapeutics announces interim leadership changesJanuary 10, 2025 | markets.businessinsider.comSpero Therapeutics Makes Interim Changes To Management After Wells Notice From SECJanuary 10, 2025 | markets.businessinsider.com Get Spero Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SPRO Media Mentions By Week SPRO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SPRO News Sentiment▼1.301.04▲Average Medical News Sentiment SPRO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SPRO Articles This Week▼31▲SPRO Articles Average Week Get the Latest News and Ratings for SPRO and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Spero Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Compass Therapeutics News I-Mab News Corvus Pharmaceuticals News Kamada News Aura Biosciences News Aquestive Therapeutics News Olema Pharmaceuticals News Rocket Pharmaceuticals News Y-mAbs Therapeutics News Vigil Neuroscience News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SPRO) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spero Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access